论文部分内容阅读
目的:观察孚来迪(瑞格列奈)对2型糖尿病病人空腹血糖(FBG)、餐后血糖(PBG)、糖化血红蛋白(HbA1 c)、空腹及餐后1h、2h、3h血浆胰岛素水平、血脂的作用效果。方法:本文共观察34例2型糖尿病病人,开放性研究,治疗前后自身对照。结果:孚来迪(瑞格列奈)可以使空腹血糖(FBG)及餐后血糖(PBG)下降(P <0 . 0 5 ) ,以后者更为显著;糖化血红蛋白(HbA1 c)亦显著下降(P <0 0 1 ) ,餐后1h及2h胰岛素显著提高(P <0 . 0 0 1 ) ,餐后3h胰岛素无显著差异(P >0 . 0 5 ) ;甘油三脂水平下降(P <0 . 0 1 )。结论:孚来迪(瑞格列奈)能有效地纠正2型糖尿病病人早期快速胰岛素分泌峰缺失,降低空腹及餐后血糖,最终使糖化血红蛋白及甘油三脂均下降,降低其慢性并发症的发生。此外,其快进快出的特点,使病人有良好的顺应性,并且未发现严重副作用。
OBJECTIVE: To observe the effect of Fudelaidi (Repaglinide) on fasting blood glucose (FBG), postprandial blood glucose (PBG), HbA1c, fasting and 1h, 2h, 3h postprandial plasma insulin in type 2 diabetic patients, Effect of blood lipids. Methods: A total of 34 patients with type 2 diabetes mellitus were observed in this study. They were open-ended and self-controlled before and after treatment. Results: Repaglinide decreased fasting blood glucose (FBG) and postprandial blood glucose (PBG) (P <0.05), and the latter became more pronounced. HbA1 c also decreased significantly (P <0.01), insulin at 1h and 2h after meal significantly increased (P <0.01), insulin at 3h postprandial had no significant difference (P> 0.05), triglyceride level decreased (P < 0. 0 1). CONCLUSION: Repaglinide can effectively correct the early rapid insulin secretion peak loss and reduce the fasting and postprandial blood glucose in type 2 diabetic patients, and eventually decrease both HbA1c and triglycerides and reduce their chronic complications occur. In addition, its fast-moving fast out of the characteristics of patients with good compliance, and found no serious side effects.